What this means
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 50 and over
- Where
- 7 sites
The science
- Registered title
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
- Trial ID
- NCT07481604 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Herpes Zoster
- What is tested
- Shingrix, CVI-VZV-001
- Sponsor
- Aribio Lab Co., Ltd.
- Ages
- 50 Years to no maximum
- Dates
- First posted Mar 19, 2026 · updated Oct 28, 2026
Registry summary
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Sites (7)
- Kyungpook National University Chilgok Hospital, Daegu, Daegu, South Korea
- CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, South Korea
- Yongin Severance Hospital, Yonsei University Health System, Yongin, Gyeonggi-do, South Korea
- Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, South Korea
- The Catholic University of Korea Eunpyeong St. Mary's Hospital, Seoul, Seoul, South Korea
- Chung-Ang University Hospital, Seoul, Seoul, South Korea
- Ewha Womans University Seoul Hospital, Seoul, Seoul, South Korea